Data Insights

PRT-2527 by Prelude Therapeutics for Sarcomas: Likelihood of Approval

PRT-2527 is under clinical development by Prelude Therapeutics and currently in Phase I for Sarcomas. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - PRT-2527 in Sarcomas

Data Insights

PRT-2527 by Prelude Therapeutics for T-Cell Lymphomas: Likelihood of Approval

PRT-2527 is under clinical development by Prelude Therapeutics and currently in Phase I for T-Cell Lymphomas. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - PRT-2527 in T-Cell Lymphomas

Data Insights

PRT-2527 by Prelude Therapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

PRT-2527 is under clinical development by Prelude Therapeutics and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - PRT-2527 in Diffuse Large B-Cell Lymphoma

Data Insights

PRT-2527 by Prelude Therapeutics for Follicular Lymphoma: Likelihood of Approval

PRT-2527 is under clinical development by Prelude Therapeutics and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - PRT-2527 in Follicular Lymphoma

Data Insights

PRT-2527 by Prelude Therapeutics for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval

PRT-2527 is under clinical development by Prelude Therapeutics and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - PRT-2527 in Primary Mediastinal B-Cell Lymphoma

Data Insights

PRT-2527 by Prelude Therapeutics for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

PRT-2527 is under clinical development by Prelude Therapeutics and currently in Phase I for Human Epidermal Growth Factor Receptor 2...

Likelihood of Approval and Phase Transition Success Rate Model - PRT-2527 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

Data Insights

PRT-2527 by Prelude Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval

PRT-2527 is under clinical development by Prelude Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - PRT-2527 in Non-Small Cell Lung Cancer

Data Insights

PRT-2527 by Prelude Therapeutics for Solid Tumor: Likelihood of Approval

PRT-2527 is under clinical development by Prelude Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - PRT-2527 in Solid Tumor

Data Insights

PRT-2527 by Prelude Therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

PRT-2527 is under clinical development by Prelude Therapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...

Likelihood of Approval and Phase Transition Success Rate Model - PRT-2527 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)